{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:44:23Z","timestamp":1791204263896,"version":"4.2.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM19\/00160"],"award-info":[{"award-number":["CM19\/00160"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI16\/01740"],"award-info":[{"award-number":["PI16\/01740"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Instituto de Salud Carlos III, Gobierno de Espa\u00f1a","award":["COV20\/00005"],"award-info":[{"award-number":["COV20\/00005"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Excessive interleukin-6 signaling is a key factor contributing to the cytokine release syndrome implicated in clinical manifestations of COVID-19. Preliminary results suggest that tocilizumab, a humanized monoclonal anti-interleukin-6 receptor antibody, may be beneficial in severely ill patients, but no data are available on earlier stages of disease. An anticipated blockade of interleukin-6 might hypothetically prevent the catastrophic consequences of the overt cytokine storm. We evaluated early-given tocilizumab in patients hospitalized with COVID-19, and identified outcome predictors. Consecutive patients with initial Sequential-Organ-Failure-Assessment (SOFA) score\u2009&lt;\u20093 fulfilling pre-defined criteria were treated with tocilizumab. Serial plasma biomarkers and nasopharyngeal swabs were collected. Of 193 patients admitted with COVID-19, 64 met the inclusion criteria. After tocilizumab, 49 (76.6%) had an early favorable response. Adjusted predictors of response were gender, SOFA score, neutrophil\/lymphocyte ratio, Charlson comorbidity index and systolic blood pressure. At week-4, 56.1% of responders and 30% of non-responders had cleared the SARS-CoV-2 from nasopharynx. Temporal profiles of interleukin-6, C-reactive protein, neutrophil\/lymphocyte ratio, NT-ProBNP, D-dimer, and cardiac-troponin-I differed according to tocilizumab response and discriminated final in-hospital outcome. No deaths or disease recurrences were observed. Preemptive therapy with tocilizumab was safe and associated with favorable outcomes in most patients. Biological and clinical markers predicted outcomes.<\/jats:p>","DOI":"10.1038\/s41598-020-74001-3","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:03:22Z","timestamp":1602151402000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Preemptive interleukin-6 blockade in patients with COVID-19"],"prefix":"10.1038","volume":"10","author":[{"given":"Luc\u00eda","family":"Guill\u00e9n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Padilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanesa","family":"Agull\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Alberto","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillermo","family":"Telenti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Garc\u00eda-Abell\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ngela","family":"Botella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar","family":"Masi\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"74001_CR1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2020.0994","author":"C Wu","year":"2020","unstructured":"Wu, C. et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. https:\/\/doi.org\/10.1001\/jamainternmed.2020.0994 (2020) (Epub ahead of print).","journal-title":"JAMA Intern. Med."},{"key":"74001_CR2","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s12967-020-02339-3","volume":"18","author":"B Fu","year":"2020","unstructured":"Fu, B., Xu, X. & Wei, H. Why tocilizumab could be an effective treatment for severe COVID-19?. J. Transl. Med. 18, 164 (2020).","journal-title":"J. Transl. Med."},{"key":"74001_CR3","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwaa041","author":"Y Zhou","year":"2020","unstructured":"Zhou, Y. et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. https:\/\/doi.org\/10.1093\/nsr\/nwaa041 (2020) (Epub ahead of print).","journal-title":"Natl. Sci. Rev."},{"key":"74001_CR4","doi-asserted-by":"publisher","first-page":"102452","DOI":"10.1016\/j.jaut.2020.102452","volume":"111","author":"B Liu","year":"2020","unstructured":"Liu, B., Li, M., Zhou, Z., Guan, X. & Xiang, Y. Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. J. Autoimmun. 111, 102452 (2020).","journal-title":"J. Autoimmun."},{"key":"74001_CR5","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1007\/s00134-020-05991-x","volume":"46","author":"QR Ruan","year":"2020","unstructured":"Ruan, Q. R., Yang, K., Wang, W. X., Jiang, L. Y. & Song, J. X. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care. Med. 46, 846\u2013848 (2020).","journal-title":"Intensive Care. Med."},{"key":"74001_CR6","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2217\/imt-2016-0020","volume":"8","author":"T Tanaka","year":"2016","unstructured":"Tanaka, T., Narazaki, M. & Kishimoto, T. Immunotherapeutic implications of IL-6 blockade for cytokine storm. Immunotherapy 8, 959\u2013970 (2016).","journal-title":"Immunotherapy"},{"key":"74001_CR7","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(03)15326-3","volume":"363","author":"A Pathan","year":"2004","unstructured":"Pathan, A. et al. Role of interleukin 6 in myocardial dysfunction of meningococcal septic shock. Lancet 363, 203\u2013209 (2004).","journal-title":"Lancet"},{"issue":"20","key":"74001_CR8","first-page":"30312","volume":"S1473\u20133099","author":"BJ Gaborit","year":"2020","unstructured":"Gaborit, B. J. et al. Plea for multitargeted interventions for severe COVID-19. Lancet Infect. Dis. S1473\u20133099(20), 30312\u201330321 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"74001_CR9","doi-asserted-by":"publisher","first-page":"105954","DOI":"10.1016\/j.ijantimicag.2020.105954","volume":"55","author":"C Zhang","year":"2020","unstructured":"Zhang, C., Wu, Z., Li, J. W., Zhao, H. & Wang, G. Q. Cytokine release syndrome in severe COVID-19: Interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int. J. Antimicrob. Agents 55, 105954 (2020).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"74001_CR10","doi-asserted-by":"publisher","first-page":"10970","DOI":"10.1073\/pnas.2005615117","volume":"117","author":"X Xu","year":"2020","unstructured":"Xu, X. et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc. Natl. Acad. Sci. USA 117, 10970\u201310975 (2020).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"74001_CR11","doi-asserted-by":"publisher","first-page":"102568","DOI":"10.1016\/j.autrev.2020.102568","volume":"19","author":"P Toniati","year":"2020","unstructured":"Toniati, P. et al. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy. Autoimmun. Rev. 19, 102568 (2020).","journal-title":"Autoimmun. Rev."},{"key":"74001_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25964","author":"R Alattar","year":"2020","unstructured":"Alattar, R. et al. Tocilizumab for the treatment of severe coronavirus disease 2019 [published online ahead of print, 2020 May 5]. J. Med. Virol. https:\/\/doi.org\/10.1002\/jmv.25964 (2020) (Epub ahead of print).","journal-title":"J. Med. Virol."},{"key":"74001_CR13","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1002\/jmv.25801","volume":"92","author":"P Luo","year":"2020","unstructured":"Luo, P. et al. Tocilizumab treatment in COVID-19: A single center experience [published online ahead of print, 2020 Apr 6]. J. Med. Virol. 92, 814\u2013818 (2020).","journal-title":"J. Med. Virol."},{"key":"74001_CR14","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.3389\/fmicb.2019.01057","volume":"10","author":"L Velazquez-Salinas","year":"2019","unstructured":"Velazquez-Salinas, L., Verdugo-Rodriguez, A. & Rodriguez, L. L. The role of interleukin 6 during viral infections. Front. Microbiol. 10, 1057 (2019).","journal-title":"Front. Microbiol."},{"key":"74001_CR15","doi-asserted-by":"publisher","first-page":"102537","DOI":"10.1016\/j.autrev.2020.102537","volume":"19","author":"D McGonagle","year":"2020","unstructured":"McGonagle, D., Sharif, K., O\u2019Regan, A. & Bridgewood, C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 19, 102537 (2020).","journal-title":"Autoimmun. Rev."},{"key":"74001_CR16","doi-asserted-by":"publisher","first-page":"43829","DOI":"10.1038\/srep43829","volume":"7","author":"ML Yang","year":"2017","unstructured":"Yang, M. L. et al. IL-6 ameliorates acute lung injury in influenza virus infection. Sci. Rep. 7, 43829 (2017).","journal-title":"Sci. Rep."},{"key":"74001_CR17","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1126\/science.1208421","volume":"334","author":"JA Harker","year":"2011","unstructured":"Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334, 825\u2013829 (2011).","journal-title":"Science"},{"key":"74001_CR18","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1093\/intimm\/dxh285","volume":"17","author":"C Rogez-Kreuz","year":"2005","unstructured":"Rogez-Kreuz, C. et al. Involvement of IL-6 in the anti-human immunodeficiency virus activity of IFN-tau in human macrophages. Int. Immunol. 17, 1047\u20131057 (2005).","journal-title":"Int. Immunol."},{"key":"74001_CR19","doi-asserted-by":"publisher","first-page":"8479","DOI":"10.1128\/JVI.00724-14","volume":"88","author":"W Hou","year":"2014","unstructured":"Hou, W., Jin, Y. H., Kang, H. S. & Kim, B. S. Interleukin-6 (IL-6) and IL-17 synergistically promote viral persistence by inhibiting cellular apoptosis and cytotoxic T cell function. J. Virol. 88, 8479\u20138489 (2014).","journal-title":"J. Virol."},{"key":"74001_CR20","doi-asserted-by":"publisher","first-page":"10501","DOI":"10.1038\/srep10501","volume":"5","author":"W Wu","year":"2015","unstructured":"Wu, W. et al. TLR ligand induced IL-6 counter-regulates the anti-viral CD8(+) T cell response during an acute retrovirus infection. Sci. Rep. 5, 10501 (2015).","journal-title":"Sci. Rep."},{"key":"74001_CR21","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.3389\/fmicb.2018.01891","volume":"9","author":"L Velazquez-Salinas","year":"2018","unstructured":"Velazquez-Salinas, L. et al. Increased virulence of an epidemic strain of vesicular stomatitis virus is associated with interference of the innate response in pigs. Front. Microbiol. 9, 1891 (2018).","journal-title":"Front. Microbiol."},{"key":"74001_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1089\/088282403763635456","volume":"16","author":"E Wattrang","year":"2003","unstructured":"Wattrang, E., Jessett, D. M., Yates, P., Fuxler, L. & Hannant, D. Experimental infection of ponies with equine influenza A2 (H3N8) virus strains of different pathogenicity elicits varying interferon and interleukin-6 responses. Viral. Immunol. 16, 57\u201367 (2003).","journal-title":"Viral. Immunol."},{"key":"74001_CR23","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","volume":"39","author":"R Channappanavar","year":"2017","unstructured":"Channappanavar, R. & Perlman, S. Pathogenic human coronavirus infections: Causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 39, 529\u2013539 (2017).","journal-title":"Semin. Immunopathol."},{"key":"74001_CR24","first-page":"e6","volume":"81","author":"Y Liu","year":"2020","unstructured":"Liu, Y. et al. Neutrophil-to-lymphocyte ratio as an independent risk factor for mortality in hospitalized patients with COVID-19. J. Infect. 81, e6\u2013e12 (2020).","journal-title":"J. Infect."},{"key":"74001_CR25","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1186\/s12967-020-02374-0","volume":"18","author":"J Liu","year":"2020","unstructured":"Liu, J. et al. Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J. Transl. Med. 18, 206 (2020).","journal-title":"J. Transl. Med."},{"issue":"10229","key":"74001_CR26","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(20)30566-3","volume":"395","author":"F Zhou","year":"2020","unstructured":"Zhou, F., Yu, T. & Du, R. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet 395(10229), 1054\u20131062 (2020).","journal-title":"Lancet"},{"key":"74001_CR27","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","volume":"7","author":"M Levi","year":"2020","unstructured":"Levi, M., Thachil, J., Iba, T. & Levy, J. H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 7, e438\u2013e440 (2020).","journal-title":"Lancet Haematol."},{"key":"74001_CR28","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.3389\/fimmu.2019.03150","volume":"10","author":"M Nosaka","year":"2020","unstructured":"Nosaka, M. et al. Crucial involvement of IL-6 in thrombus resolution in mice via macrophage recruitment and the induction of proteolytic enzymes. Front. Immunol. 10, 3150 (2020).","journal-title":"Front. Immunol."},{"key":"74001_CR29","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1161\/ATVBAHA.119.313137","volume":"40","author":"Y Zhang","year":"2020","unstructured":"Zhang, Y. et al. IL (interleukin)-6 contributes to deep vein thrombosis and is negatively regulated by miR-338-5p. Arterioscler. Thromb. Vasc. Biol. 40, 323\u2013334 (2020).","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"74001_CR30","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa272","author":"Z Wang","year":"2020","unstructured":"Wang, Z., Yang, B., Li, Q., Wen, L. & Zhang, R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin. Infect. Dis https:\/\/doi.org\/10.1093\/cid\/ciaa272 (2020).","journal-title":"Clin. Infect. Dis"},{"issue":"10228","key":"74001_CR31","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S0140-6736(20)30558-4","volume":"395","author":"T Wang","year":"2020","unstructured":"Wang, T. et al. Comorbidities and multi-organ injuries in the treatment of COVID-19. Lancet 395(10228), e52 (2020).","journal-title":"Lancet"},{"key":"74001_CR32","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamacardio.2020.1017","volume":"5","author":"T Guo","year":"2020","unstructured":"Guo, T. et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. 5, 811\u2013818 (2020).","journal-title":"JAMA Cardiol."},{"key":"74001_CR33","doi-asserted-by":"publisher","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","volume":"55","author":"WJ Guan","year":"2020","unstructured":"Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. Eur. Respir. J. 55, 2000547 (2020).","journal-title":"Eur. Respir. J."},{"key":"74001_CR34","doi-asserted-by":"publisher","first-page":"e21","DOI":"10.1016\/S2213-2600(20)30116-8","volume":"8","author":"L Fang","year":"2020","unstructured":"Fang, L., Karakiulakis, G. & Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? [published correction appears in Lancet Respir Med. 2020 May 18]. Lancet Respir. Med. 8, e21 (2020).","journal-title":"Lancet Respir. Med."},{"key":"74001_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.phrs.2017.06.005","volume":"125","author":"XC Li","year":"2017","unstructured":"Li, X. C., Zhang, J. & Zhuo, J. L. The vasoprotective axes of the renin\u2013angiotensin system: Physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacol. Res. 125, 21\u201338 (2017).","journal-title":"Pharmacol. Res."},{"key":"74001_CR36","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis. (Springer, New York, 2016). ISBN 978-3-319-24277-4. https:\/\/ggplot2.tidyverse.org."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74001-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74001-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T20:37:33Z","timestamp":1670359053000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-74001-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["74001"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-74001-3","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"30 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16826"}}